Carolyn Nickson

The impact of the Covid-19 pandemic on breast cancer early detection and screening

Jonine D Figueroa, Ewan Gray, Nora Pashayan, Silvia Deandrea, Andre Karch, Diama Bhadra Vale, Kenneth Elder, Pietro Procopio, Nicolien T van Ravesteyn, Miriam Mutabi, Karen Canfell, Carolyn Nickson

Journal article  |  2021  |  PREVENTIVE MEDICINE

The COVID-19 pandemic affects mortality and morbidity, with disruptions expected to continue for some time, with access to timely ..

965The estimated impact of improved breast screening tests targeted at women with dense breasts

Pietro Procopio, Louiza Velentzis, A Dennis Petrie, G Bruce Mann, Anne M Kavanagh, A Ray Watson, Karinna Saxby, Elizabeth Korevaar, Sarah Carr, Hannah Bromley, Karen Canfell, Carolyn Nickson

Journal article  |  2021  |  International Journal of Epidemiology

Abstract Background There is increasing interest in risk-based breast cancer s..

906Can mammographic density add value to the Gail model in risk-stratifying women in BreastScreen Australia?

Louiza Velentzis, Pietro Procopio, Sarah Carr, Lisa Devereux, Bruce Mann, Paul James, Grant Lee, Cameron Wellard, Yulia Arzhaeva, Carolyn Nickson

Journal article  |  2021  |  International Journal of Epidemiology

Abstract Background There is significant interest in personalised, risk-based ..

CN3 It's All in the Family: Microsimulation Modelling of Genetic Testing

L Petelin, M Cunich, P Procopio, C Nickson, I Campbell, AH Trainer

Conference Proceedings  |  2021  |  Value in Health

Breast cancer screening and overdiagnosis

Jean-Luc Bulliard, Anna-Belle Beau, Sisse Njor, Wendy Yi-Ying Wu, Pietro Procopio, Carolyn Nickson, Elsebeth Lynge

Journal article  |  2021  |  INTERNATIONAL JOURNAL OF CANCER

Overdiagnosis is a harmful consequence of screening which is particularly challenging to estimate. An unbiased setting to measure ..

Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer

Karinna Saxby, Carolyn Nickson, G Bruce Mann, Allan Park, Hannah Bromley, Louiza Velentzis, Pietro Procopio, Karen Canfell, Dennis Petrie

Journal article  |  2021  |  EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH

Background:Although evaluations of breast cancer screening programs frequently estimate quality-adjusted life-year (QALY) losses b..

How has COVID-19 impacted cancer screening? Adaptation of services and the future outlook in Australia

Eleonora Feletto, Paul Grogan, Carolyn Nickson, Megan Smith, Karen Canfell

Journal article  |  2020  |  PUBLIC HEALTH RESEARCH & PRACTICE

The coronavirus disease 2019 (COVID-19) pandemic has caused major disruptions to many aspects of life in Australia and globally. T..

The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density

Dane Cheasley, Lisa Devereux, Siobhan Hughes, Carolyn Nickson, Pietro Procopio, Grant Lee, Na Li, Vicki Pridmore, Kenneth Elder, G Bruce Mann, Tanjina Kader, Simone M Rowley, Stephen B Fox, David Byrne, Hugo Saunders, Kenji M Fujihara, Belle Lim, Kylie L Gorringe, Ian G Campbell

Journal article  |  2020  |  NPJ BREAST CANCER

Mammographic density (MD) influences breast cancer risk, but how this is mediated is unknown. Molecular differences between breast..

The financial impact of a breast cancer detected within and outside of screening: lessons from the Australian Lifepool cohort

Karinna Saxby, Carolyn Nickson, G Bruce Mann, Louiza Velentzis, Hannah L Bromley, Pietro Procopio, Karen Canfell, Dennis Petrie

Journal article  |  2020  |  AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH

OBJECTIVE: To determine the government and out-of-pocket community costs (out-of-hospital medical services and prescription medici..

Valuing preferences for treating screen detected ductal carcinoma in situ

Hannah L Bromley, G Bruce Mann, Dennis Petrie, Carolyn Nickson, Daniel Rea, Tracy E Roberts

Journal article  |  2019  |  EUROPEAN JOURNAL OF CANCER

BACKGROUND: Mammographic screening reduces breast cancer mortality but may lead to the overdiagnosis and overtreatment of low-risk..